mRNA vaccines in the rheumatologist's future
Authors' conclusion
A number of mRNA vaccines against viral pathogens are in early to late phase development.
Study context
- Population
- Clinical and immunologic studies of mRNA vaccines against infectious diseases
- Outcome
- Status of approved and in-development mRNA vaccines for infectious diseases
Main finding
As reported in the abstract
- Approved mRNA vaccines include those against SARS CoV-2; immunogenic, good protection against severe disease
- A number of mRNA influenza vaccines in development, incl. phase 3 studies
- Others in development target Epstein-Barr Virus (EBV), Cytomegalovirus (CMV), VZV and respiratory syncytial virus (RSV)
- Many likely to be indicated for immunosuppressed populations, incl. autoimmune inflammatory diseases
Original publication
mRNA vaccines in the rheumatologist's future. Semin Arthritis Rheum. Published 22 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →